Amneal Pharmaceuticals, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Amneal Pharmaceuticals, Inc. (AMRX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are AMRX insiders buying or selling?
In the last 12 months, Amneal Pharmaceuticals, Inc. insiders reported 0 open-market purchases ($0) and 6 sales ($9.8M) — net selling of $9.8M. Since May 2018, Trabud has recorded 66 Form 4 filings for AMRX: 22 buys ($13.0M) and 44 sells ($934.2M).
Source: SEC EDGAR Form 4
Key Statistics (May 2018 – Aug 14, 2026)
Total Form 4 filings
66
SEC EDGAR
Insider filers
23
Insider buys (22)
$13.0M
Insider sells (44)
$934.2M
Insider sentiment
Net sellingNet insider flow of $921.2M in net selling since May 2018, and $9.8M in net selling over the last 12 months.
Recent AMRX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | John Kiely | Director | Sale | 50.0K | $17.64 | $882.0K | SEC ↗ |
| Aug 13, 2026 | Nikita Shah | Executive Vice President | Sale | 146.4K | $17.51 | $2.6M | SEC ↗ |
| Aug 13, 2026 | Jason B. Daly | EVP, Chief Legal Officer | Sale | 216.6K | $17.41 | $3.8M | SEC ↗ |
| May 12, 2026 | Deborah M. Autor | Director | Sale | 34.8K | $12.94 | $450.6K | SEC ↗ |
| Nov 19, 2025 | Ted C Nark | Director | Sale | 50.0K | $11.72 | $586.0K | SEC ↗ |
| Nov 14, 2025 | Nikita Shah | Executive Vice President | Sale | 131.9K | $11.92 | $1.6M | SEC ↗ |
| Aug 28, 2025 | John Kiely | Director | Sale | 32.0K | $9.23 | $295.4K | SEC ↗ |
| Aug 25, 2025 | Nikita Shah | Executive Vice President | Sale | 120.8K | $9.65 | $1.2M | SEC ↗ |
| Aug 22, 2025 | Andrew S Boyer | Executive Vice President | Sale | 279.2K | $9.38 | $2.6M | SEC ↗ |
| Aug 15, 2025 | Nikita Shah | Executive Vice President | Sale | 71.7K | $9.29 | $666.0K | SEC ↗ |
| Aug 13, 2025 | Nikita Shah | Executive Vice President | Sale | 50.0K | $9.04 | $452.0K | SEC ↗ |
| Aug 13, 2025 | Jason B. Daly | EVP, Chief Legal Officer | Sale | 22.0K | $9.05 | $199.1K | SEC ↗ |
| Aug 13, 2025 | Andrew S Boyer | Executive Vice President | Sale | 33.4K | $9.05 | $302.6K | SEC ↗ |
| Jun 18, 2025 | Patel Gautam | Director | Sale | 94.9K | $8.02 | $761.1K | SEC ↗ |
| Jun 12, 2025 | Patel Gautam | Director | Sale | 56.4K | $8.02 | $452.5K | SEC ↗ |
| May 19, 2025 | Nikita Shah | Executive Vice President | Sale | 49.1K | $7.58 | $372.5K | SEC ↗ |
| May 13, 2025 | John Kiely | Director | Sale | 50.0K | $7.59 | $379.5K | SEC ↗ |
| May 6, 2025 | Patel Gautam | Director | Sale | 8.7K | $8.00 | $69.3K | SEC ↗ |
| Apr 2, 2025 | Patel Gautam | Director | Sale | 80.0K | $8.30 | $664.0K | SEC ↗ |
| Mar 17, 2025 | Patel Tushar Bhikhubhai | 10% Owner | Sale | 5.0M | $8.35 | $41.8M | SEC ↗ |
| Mar 7, 2025 | Andrew S Boyer | Executive Vice President | Sale | 125.0K | $8.89 | $1.1M | SEC ↗ |
| Mar 7, 2025 | Jason B. Daly | EVP, Chief Legal Officer | Sale | 90.0K | $8.80 | $792.2K | SEC ↗ |
| Mar 7, 2025 | Tasos Konidaris | Executive Vice President & CFO | Sale | 100.0K | $8.91 | $891.0K | SEC ↗ |
| Mar 7, 2025 | Emily Peterson Alva | Director | Sale | 80.0K | $8.90 | $712.0K | SEC ↗ |
| Mar 6, 2025 | Patel Gautam | Director | Sale | 80.0K | $8.90 | $712.0K | SEC ↗ |
Showing the 25 most recent of 66 Form 4 filings for Amneal Pharmaceuticals, Inc..
Most active AMRX insiders
- Nikita Shah10 filings
- Patel Gautam10 filings
- Andrew S Boyer7 filings
- Jason B. Daly5 filings
- John Kiely5 filings
Ask anything about AMRX insider activity
Use Trabud's AI agent to query Amneal Pharmaceuticals, Inc.'s Form 4 history in plain English — "Show me AMRX CEO purchases this year" or compare it against any other ticker.
Open the AI agentAMRX insider trading FAQ
Are Amneal Pharmaceuticals, Inc. insiders buying or selling?
In the last 12 months, Amneal Pharmaceuticals, Inc. insiders reported 0 open-market purchases ($0) and 6 sales ($9.8M) — net selling of $9.8M. Since May 2018, Trabud has recorded 66 Form 4 filings for AMRX: 22 buys ($13.0M) and 44 sells ($934.2M). Over the full record that is net selling of $921.2M.
How many insiders trade AMRX stock?
23 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Amneal Pharmaceuticals, Inc.. The most recent filing was accepted on Aug 14, 2026.
Where does Trabud get AMRX insider trading data?
All AMRX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.